Equities researchers at StockNews.com started coverage on shares of Acorda Therapeutics (NASDAQ:ACOR – Get Rating) in a research report issued to clients and investors on Monday. The brokerage set a "hold" rating on the biopharmaceutical company's stock.
Acorda Therapeutics Stock Down 13.3 %
ACOR stock opened at $0.29 on Monday. The company has a market cap of $6.95 million, a price-to-earnings ratio of -0.03 and a beta of 0.45. The company has a current ratio of 1.86, a quick ratio of 1.49 and a debt-to-equity ratio of 2.10. Acorda Therapeutics has a 12 month low of $0.28 and a 12 month high of $4.99. The firm has a 50-day moving average of $0.42 and a two-hundred day moving average of $0.79.
Get Acorda Therapeutics alerts:Acorda Therapeutics (NASDAQ:ACOR – Get Rating) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($2.78) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($2.42). The business had revenue of $31.05 million during the quarter. Acorda Therapeutics had a negative net margin of 98.25% and a negative return on equity of 90.29%.
Hedge Funds Weigh In On Acorda Therapeutics
Hedge funds have recently made changes to their positions in the stock. Millennium Management LLC boosted its position in Acorda Therapeutics by 661.2% in the 2nd quarter. Millennium Management LLC now owns 311,509 shares of the biopharmaceutical company's stock valued at $145,000 after buying an additional 270,588 shares during the period. Renaissance Technologies LLC boosted its position in Acorda Therapeutics by 27.4% in the 2nd quarter. Renaissance Technologies LLC now owns 901,318 shares of the biopharmaceutical company's stock valued at $420,000 after buying an additional 194,100 shares during the period. Virtu Financial LLC purchased a new position in Acorda Therapeutics in the 2nd quarter valued at approximately $68,000. Finally, Prudential Financial Inc. purchased a new position in Acorda Therapeutics in the 2nd quarter valued at approximately $28,000. Hedge funds and other institutional investors own 50.24% of the company's stock.About Acorda Therapeutics
(Get Rating)
Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe.
Further Reading
- Get a free copy of the StockNews.com research report on Acorda Therapeutics (ACOR)
- Can Caterpillar Claw Higher in a Falling Market?
- Is Dave & Buster's Immune to High Inflation and Lower Spending?
- Should These 3 Top-Performing Mid-Caps Be On Your Watchlist?
- Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
- MarketBeat: Week in Review 9/19 – 9/23
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.